Remed Co

Remed Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Remed Co (302550.KQ) as of Nov 19, 2026 is -13.31 M KRW. In the previous year, Stock-Based Compensation (SBC) was 59.81 M KRW — a change of -122.25% (lower).

Stock-Based Compensation

-13.31 MKRW

YoY

-122.25%

Last updated:

Stock-Based Compensation (SBC) of Remed Co is 2025 -13.31 M KRW. Stock-Based Compensation (SBC) of Remed Co was 2024 59.81 M KRW. It decreases by -122.25% lower compared to the previous year.

The Remed Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
558.44 M KRW
Jan 1, 2021
168.11 M KRW
Jan 1, 2022
80.87 M KRW
Jan 1, 2023
120.22 M KRW
Jan 1, 2024
59.81 M KRW
Jan 1, 2025
-13.31 M KRW
The Remed Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
-13.31 MKRW-122.25%
59.81 MKRW-50.25%
120.22 MKRW+48.66%
80.87 MKRW-51.90%
168.11 MKRW-69.90%
558.44 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Stock-Based Compensation (SBC) of Remed Co is -13.31 M KRW in 2025.

Stock-Based Compensation (SBC) of Remed Co changed from 59.81 M KRW to -13.31 M KRW, representing a -122.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Remed Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Remed Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Remed Co

All Key Metrics — Remed Co